Antibody-Based Correlates of Protection Against Cholera Analysis of a Challenge Study in a Cholera-Naïve Population

Douglas J Haney, Michael D Lock, Jakub K Simon, Jason Harris, Marc Gurwith, Douglas J Haney, Michael D Lock, Jakub K Simon, Jason Harris, Marc Gurwith

Abstract

Immunologic correlates of protection can be used to infer vaccine efficacy for populations in which challenge trials or field studies are infeasible. In a recent cholera challenge trial (WH Cohen et al, Clinical Infectious Disease 62: 1329-1335, 2016), 134 North American cholera-naïve volunteers were randomized to receive either the live, attenuated single-dose cholera vaccine CVD 103-HgR or placebo, and titers of vibriocidal antibodies against classical Inaba were assessed 10 days after treatment. Subsequent to the immunologic evaluation, each subject ingested a fixed quantity of virulent V. cholerae O1 El Tor Inaba. Data from this trial suggest that vaccine-induced increase in vibriocidal antibody titer prior to challenge is tightly linked with protection: 51/51 vaccinees with post-vaccination vibriocidal titers >= 2560 were protected against moderate/severe cholera, and 60/62 vaccinees who seroconverted, or experienced a 4-fold or greater increase in vibriocidal titer relative to pre-vaccination levels, were similarly protected. Atypically high vibriocidal titers were observed in some placebo subjects; protection was limited in these individuals and differed substantially from the level of protection experienced by vaccinees with the same post-vaccination titers. Since only 1 of 66 placebo recipients experienced seroconversion, seroconversion was found to be uniquely associated with vaccination and insensitive to the effects of factors that can cause titers to be elevated but are weakly associated with protection. Thus, vibriocidal seroconversion was found to be better than vibriocidal titer for inferring vaccine efficacy in cholera-naïve populations for which studies based upon exposure to V. cholerae are impractical.

Copyright © 2017 Haney et al.

Figures

FIG 1
FIG 1
Overlap of absolute vibriocidal antibody titer distribution in vaccinees and placebo recipients and overlap of fold increase in vibriocidal antibody titer.

References

    1. Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Pasetti MF, Simon JK, Szabo F, Tennant S, Levine MM. 2016. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin Infect Dis 62:1329–1335. doi:10.1093/cid/ciw145.
    1. Tacket CO, Losonsky G, Nataro JP, Cryz SJ, Edelman R, Kaper JB, Levine MM. 1992. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 166:837–841. doi:10.1093/infdis/166.4.837.
    1. Kauffman RC, Bhuiyan TR, Nakajima R, Mayo-Smith LM, Rashu R, Hoq MR, Chowdhury F, Khan AI, Rahman A, Bhaumik SK, Harris L, O'Neal JT, Trost JF, Alam NH, Jasinskas A, Dotsey E, Kelly M, Charles RC, Xu P, Kováč P, Calderwood SB, Ryan ET, Felgner PL, Qadri F, Wrammert J, Harris JB. 2016. Single-cell analysis of the plasmablast response to Vibrio cholerae demonstrates expansion of cross-reactive memory B cells. mBio 7:e02021-16. doi:10.1128/mBio.02021-16.
    1. Mosley WH, Benenson AS, Barui R. 1968. A serological survey for cholera antibodies in rural East Pakistan. Bull World Health Organ 38:335–346.
    1. Patel SM, Rahman MA, Mohasin M, Riyadh MA, Leung DT, Alam MM, Chowdhury F, Khan AI, Weil AA, Aktar A, Nazim M, LaRocque RC, Ryan ET, Calderwood SB, Qadri F, Harris JB. 2012. Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection from household contacts of patients with cholera in Bangladesh. Clin Vaccine Immunol 19:842–848. doi:10.1128/CVI.00037-12.
    1. World Health Organization. 2004. Expert Committee on Biological Standardization: 52nd report. WHO technical report, series no. 924 World Health Organization, Geneva, Switzerland.
    1. Levine MM, Kaper JB, Black RE, Clements ML. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev 47:510–550.
    1. Cryz SJ, Levine MM, Kaper JB, Furer E, Althaus B. 1990. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral vaccine strain CVD 103-HgR in Swiss adults. Vaccine 8:577–580. doi:10.1016/0264-410X(90)90012-B.
    1. Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, Edelman R, Kaper JB, Cryz SJ, Giannella RA, Schiff G, Levine MM. 1999. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect Immun 67:6341–6345.
    1. Cauchemez S, Horby P, Fox A, Mai LQ, Thanh LT, Thai PQ, Hoa LNM, Hien NT, Ferguson NM. 2012. Influenza infection rates, measurement errors and the interpretation of paired serology. PLoS Pathog 8:e1003061. doi:10.1371/journal.ppat.1003061.
    1. Vezzulli L, Colwell RR, Pruzzo C. 2013. Ocean warming and spread of pathogenic vibrios in the aquatic environment. Microb Ecol 65:817–825. doi:10.1007/s00248-012-0163-2.
    1. Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR. 1981. Duration of infection-derived immunity to cholera. J Infect Dis 143:818–820. doi:10.1093/infdis/143.6.818.
    1. Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque ASG, Ryan ET, Qadri F, Calderwood SB. 2008. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis 2:e221. doi:10.1371/journal.pntd.0000221.
    1. Harris AM, Bhuiyan MS, Chowdhury F, Khan AI, Hossain A, Kendall EA, Rahman A, LaRocque RC, Wrammert J, Ryan ET, Qadri F, Calderwood SB, Harris JB. 2009. Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun 77:3850–3856. doi:10.1128/IAI.00369-09.
    1. Mayo-Smith LM, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Calderwood SB, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB. 2017. The live attenuated cholera vaccine CVD 103-HgR primes responses to the toxin-coregulated pilus antigen TcpA in subjects challenged with wild-type Vibrio cholerae. Clin Vaccine Immunol 24:e00470-16. doi:10.1128/CVI.00470-16.
    1. Benenson AS, Saad A, Mosley WH. 1968. Serological studies in cholera: the vibriocidal antibody response of cholera patients determined by a microtechnique. Bull World Health Organ 38:277–285.
    1. Jonckheere AR. 1954. A distribution-free K-sample test against ordered alternatives. Biometrika 41:133–145.
    1. Spearman C. 1904. The proof and measurement of association between two things. Am J Psychol 15:72–101. doi:10.2307/1412159.
    1. Clopper CJ, Pearson ES. 1934. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404–413. doi:10.1093/biomet/26.4.404.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever